The primary purpose of conducting this Phase 4 post marketing study is to assess the efficacy of AXS-05 compared to Buproprion in preventing relapse of depression symptoms in subjects who have responded to treatment with AXS-05
What is the medication?
AXS-05 is Auvelity, which is a combination of Dextromethorphan hydrobromide and Bupropion hydrochloride
Screening period: up to 4 weeks
10 week, open label AXS-05 of which there will be a 6 week response evaluation period followed by a 4 week remission evaluation and stabilization period
26 week, double blind, randomized (AXS vs Buproprion)
Follow up period: 1 week
You May Qualify If:
You meet criteria for Major Depressive Disorder (MDD) and are currently in a Major Depressive Episode for which you are in need of treatment for MDD or a change in treatment for MDD because of suboptimal response and/or intolerance to current therapy
Qualified candidates may earn up to ____ per visit. Transportation assistance to those who enroll.